Abstract
In spite of affecting the life of millions of people, chronic traumatic brain injury (TBI) has not been hitherto treatable with effective pharmacological tools. This review gives a comprehensive summary of the theoretical data supporting the pharmacological manipulation of the cholinergic system in TBI, pointing out the most urgent targets for further studies. The published clinical evidence of cholinergic treatment in TBI is critically reviewed, with emphasis on modern available cholinergic agents. The lessons from these studies are converted to detailed suggestions for further clinical testing. In addition, the treating clinicians are provided with practical advice, based on personal experience of the cholinergic treatment in over 350 TBI patients. It is concluded that cholinergic agents offer several very promising potentials for the treatment of TBI. However, the final breakthrough requires further well-conducted studies and the potential caveats of the treatment have to be acknowledged.
Keywords: Traumatic brain injury, acetylcholine, acetylcholinesterase inhibitors, drug treatment, review
Current Drug Therapy
Title: Cholinergic Treatment of Traumatic Brain Injury
Volume: 1 Issue: 2
Author(s): Olli Sakari Tenovuo
Affiliation:
Keywords: Traumatic brain injury, acetylcholine, acetylcholinesterase inhibitors, drug treatment, review
Abstract: In spite of affecting the life of millions of people, chronic traumatic brain injury (TBI) has not been hitherto treatable with effective pharmacological tools. This review gives a comprehensive summary of the theoretical data supporting the pharmacological manipulation of the cholinergic system in TBI, pointing out the most urgent targets for further studies. The published clinical evidence of cholinergic treatment in TBI is critically reviewed, with emphasis on modern available cholinergic agents. The lessons from these studies are converted to detailed suggestions for further clinical testing. In addition, the treating clinicians are provided with practical advice, based on personal experience of the cholinergic treatment in over 350 TBI patients. It is concluded that cholinergic agents offer several very promising potentials for the treatment of TBI. However, the final breakthrough requires further well-conducted studies and the potential caveats of the treatment have to be acknowledged.
Export Options
About this article
Cite this article as:
Tenovuo Sakari Olli, Cholinergic Treatment of Traumatic Brain Injury, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776930932
DOI https://dx.doi.org/10.2174/157488506776930932 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Novel Non-rodent Models of Kidney Disease
Current Molecular Medicine Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Future Perspectives on the Fibrinolytic Therapy of Intracerebral Hemorrhages
Central Nervous System Agents in Medicinal Chemistry Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry From Anti-allergic to Anti-Alzheimer ’ s: Molecular Pharmacology of Dimebon™
Current Alzheimer Research HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Combat Military Personnel and Selective Risk Factors for the Development of Dementias - A Review
Current Psychiatry Research and Reviews Targeting the Pleiotrophin/Receptor Protein Tyrosine Phosphatase β /ζ Signaling Pathway to Limit Neurotoxicity Induced by Drug Abuse
Mini-Reviews in Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Conference Report: 9th International Summer School of Neurology
CNS & Neurological Disorders - Drug Targets Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Neuromodulatory and Anti-Inflammatory Ingredient for Sensitive Skin: In Vitro Assessment
Inflammation & Allergy - Drug Targets (Discontinued) Cell Signaling Mechanisms by which Geniposide Regulates Insulin- Degrading Enzyme Expression in Primary Cortical Neurons
CNS & Neurological Disorders - Drug Targets Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design